Decision based on NIAGARA Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free and overall survival benefit
If approved, this will be the first and only perioperative immunotherapy regimen in this curative-intent setting
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.